Charles Schwab Investment Management Inc. Sells 31,718 Shares of Seres Therapeutics, Inc. $MCRB

Key Points

• Charles Schwab Investment Management decreased its stake in Seres Therapeutics by 3.7%, now holding approximately 834,107 shares valued at $584,000.
• Other hedge funds have increased their positions, with Millennium Management raising its stake by 77.2%, now owning over 1.8 million shares.
• Analysts have mixed ratings on the stock, with a recent upgrade from Wall Street Zen changing it from "sell" to "hold" and Chardan Capital placing a price target of $6.00.

Charles Schwab Investment Management Inc. trimmed its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 3.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 834,107 shares of the biotechnology company's stock after selling 31,718 shares during the period. Charles Schwab Investment Management Inc. owned approximately 9.57% of Seres Therapeutics worth $584,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MCRB. Millennium Management LLC raised its position in Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock worth $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. raised its position in Seres Therapeutics by 15.7% in the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after purchasing an additional 147,671 shares in the last quarter. SBI Securities Co. Ltd. raised its position in Seres Therapeutics by 221.8% in the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 48,013 shares in the last quarter. Northern Trust Corp raised its position in Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after purchasing an additional 44,461 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 37,866 shares in the last quarter. Institutional investors own 59.34% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MCRB shares. Wall Street Zen raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Chardan Capital reissued a "neutral" rating and issued a $6.00 price target (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $73.67.

Seres Therapeutics Price Performance

MCRB opened at $18.50 on Thursday. Seres Therapeutics, Inc. has a one year low of $6.53 and a one year high of $26.40. The company's 50 day simple moving average is $14.69 and its 200-day simple moving average is $12.11. The stock has a market capitalization of $161.88 million, a P/E ratio of -4.02 and a beta of 0.15.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($2.72) by $0.45. As a group, analysts anticipate that Seres Therapeutics, Inc. will post -0.38 EPS for the current year.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.